582 related articles for article (PubMed ID: 1922207)
21. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin.
Brake M; Loertzer H; Horsch R; Keller H
J Urol; 2000 Jun; 163(6):1697-701. PubMed ID: 10799163
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
23. Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy.
Hurle R; Losa A; Ranieri A; Graziotti P; Lembo A
J Urol; 1996 Nov; 156(5):1602-5. PubMed ID: 8863547
[TBL] [Abstract][Full Text] [Related]
24. The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder.
Boorjian SA; Zhu F; Herr HW
BJU Int; 2010 Aug; 106(3):357-61. PubMed ID: 20002665
[TBL] [Abstract][Full Text] [Related]
25. Bacillus Calmette-Guérin immunotherapy. Techniques and results.
Brosman SA
Urol Clin North Am; 1992 Aug; 19(3):557-64. PubMed ID: 1636239
[TBL] [Abstract][Full Text] [Related]
26. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression.
Andius P; Holmäng S
BJU Int; 2004 May; 93(7):980-4. PubMed ID: 15142147
[TBL] [Abstract][Full Text] [Related]
27. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy.
Ajili F; Kourda N; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Feb; 37(1):56-61. PubMed ID: 23383616
[TBL] [Abstract][Full Text] [Related]
29. Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin.
Gee JR; Jarrard DF; Bruskewitz RC; Moon TD; Hedican SP; Leverson GE; Nakada SY; Messing EM
BJU Int; 2009 Mar; 103(6):736-9. PubMed ID: 19007364
[TBL] [Abstract][Full Text] [Related]
30. A trial of bacillus Calmette-Guérin versus adriamycin in superficial bladder cancer: a South-West Oncology Group Study.
Mori K; Lamm DL; Crawford ED
Urol Int; 1986; 41(4):254-9. PubMed ID: 3538593
[TBL] [Abstract][Full Text] [Related]
31. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
[TBL] [Abstract][Full Text] [Related]
32. Diagnosis and management of superficial bladder cancer.
Amling CL
Curr Probl Cancer; 2001; 25(4):219-78. PubMed ID: 11514784
[TBL] [Abstract][Full Text] [Related]
33. Results of long-term follow-up of patients with superficial bladder carcinoma treated with intravesically applied bacillus Calmette-Guerin vaccine according to the schedule of 6 weekly + 6 monthly instillations.
Librenjak D; Situm M; Vrdoljak E; Milostić K; Gotovac J
Urol Oncol; 2012; 30(3):259-65. PubMed ID: 20843705
[TBL] [Abstract][Full Text] [Related]
34. Reactive antibodies against bacillus Calmette-Guerin heat-shock protein-65 potentially predict the outcome of immunotherapy for high-grade transitional cell carcinoma of the bladder.
Ardelt PU; Kneitz B; Adam P; Reiss C; Kocot A; Fensterle J; Chen L; Pasqualini R; Arap W; Gerharz EW; Riedmiller H
Cancer; 2010 Feb; 116(3):600-9. PubMed ID: 19957324
[TBL] [Abstract][Full Text] [Related]
35. [Muscularis mucosae invasion: prognostic factor for intravesical BCG immunotherapy failure for T1 bladder carcinoma].
Nguyen-Huu Y; Delorme G; Lillaz J; Bedgedjian I; Le Ray-Ferrières I; Chabannes E; Bernardini S; Guichard G; Bittard H; Kleinclauss F
Prog Urol; 2012 May; 22(5):284-90. PubMed ID: 22515925
[TBL] [Abstract][Full Text] [Related]
36. The effect of lubricants on viability of bacillus Calmette-Guerin for intravesical immunotherapy against bladder carcinoma.
Böhle A; Rüsch-Gerdes S; Ulmer AJ; Braasch H; Jocham D
J Urol; 1996 Jun; 155(6):1892-6. PubMed ID: 8618281
[TBL] [Abstract][Full Text] [Related]
37. [Combined treatment in patients with carcinoma in situ of the urinary bladder using intravesical pirarubicin, irradiation and hyperthermia].
Takechi T; Kawamura M; Nakagawa H; Inatsuki S; Akiyama K; Yano M; Sumiyoshi Y; Mandai K; Moriwaki S; Kataoka M
Nihon Gan Chiryo Gakkai Shi; 1990 Nov; 25(11):2724-7. PubMed ID: 2277223
[TBL] [Abstract][Full Text] [Related]
38. Intravesical bacille Calmette-Guérin-induced multiorgan failure after treatment for transitional cell carcinoma.
Kiely B; McLaughlin AM; Lynch TH; Keane J
Scand J Urol Nephrol; 2011 Sep; 45(4):278-80. PubMed ID: 21329482
[TBL] [Abstract][Full Text] [Related]
39. The persistence of bacille Calmette-Guérin in the bladder after intravesical treatment for bladder cancer.
Bowyer L; Hall RR; Reading J; Marsh MM
Br J Urol; 1995 Feb; 75(2):188-92. PubMed ID: 7850324
[TBL] [Abstract][Full Text] [Related]
40. Intravesical bacillus Calmette-Guerin for superficial bladder cancer: experience with Danish 1331 strain.
Kamat MR; Kulkarni JN; Tongaonkar HB; Dalal AV
J Urol; 1994 Nov; 152(5 Pt 1):1424-8. PubMed ID: 7933175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
